Reckitt announces millionaire investment for its Chihuahua plant

The British company Reckitt announced that it will invest more than 178 million pesos in its plant in Delicias, Chihuahua, by 2023, which adds up to 2,000 million pesos in investment for this municipality since 2016, which have been allocated to the development of technology, quality and implementation of sanitary measures inside the plant.

 “We are at a key moment for our operation and that is why we have made one of the largest economic commitments for the municipality of Delicias. We have committed to a total investment of 2,000 million pesos to take the Delicias plant, a world-class plant, to the next level. This also entails stimulating the local economy, promoting jobs in the state of Chihuahua, where more than 450 employees are already employed, and developing even more projects that benefit both the community and the environment," said Anne Engerant, senior vice president of Reckitt Latin America.

The company is a leader in the consumer industry and in Mexico employs more than 2,100 people in its four plants located in Mexico City, State of Mexico, Chihuahua and Baja California, in addition to its Research and Development Center and its corporate offices that They serve all of Latin America. 

Mexico is of great importance for the company at a global level, since here it manufactures and exports nutrition products to more than 25 countries, becoming the most important region of the group in Latin America. It has brands such as Enfamil, Chocomilk, Cal-C-Tose, Lysol, Tempra, Picot, Sico and Vanish, among others. 

The plant located in Mexico has become a strategic point for world production and has exponentially increased its participation. Recently, the multinational company received approval from the United States Food and Drug Administration (FDA) to export 300 tons of infant formula from its Delicias facilities and thus support the shortage of this product in United States, of which 150 have already been shipped in a first shipment.

Said production for the PurAmino infant formula is made on the basis of amino acids for those babies with allergies to cow's milk protein, other food allergies or various other gastrointestinal conditions, and was subjected to strict quality and safety controls. It will be distributed primarily through hospitals and other healthcare facilities, as well as select retail stores to ensure access to this critical medical product for babies who need it most and who are among the most vulnerable in this shortage.

Globally, the company employs 43,000 people in 60 countries on six continents. With its three business units: hygiene, health and nutrition, it sells 20 million products daily.